MacroGenics doses first patient in Phase 1 trial of MGC030 ADC

October 15, 2026 4:05 PM

MacroGenics, Inc. (NASDAQ: MGNX) announced that the first patient has been dosed in a Phase 1 study of MGC030, an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found